La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
ORIC Pharmaceuticals Gestione
Gestione criteri di controllo 4/4
ORIC Pharmaceuticals' Il CEO è Jacob Chacko, nominato in May2018, e ha un mandato di 6.25 anni. la retribuzione annua totale è $ 3.15M, composta da 18.9% di stipendio e 81.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.03% delle azioni della società, per un valore di $ 7.36M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.3 anni e 4.3 anni.
Informazioni chiave
Jacob Chacko
Amministratore delegato
US$3.2m
Compenso totale
Percentuale dello stipendio del CEO | 18.9% |
Mandato del CEO | 6.3yrs |
Proprietà del CEO | 1.0% |
Durata media del management | 5.3yrs |
Durata media del Consiglio di amministrazione | 4.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation
Aug 21ORIC Pharmaceuticals Stock: Too Early To Justify This Valuation
Jul 29ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value
Jul 17We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
May 08ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains
Mar 13We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
Jan 18We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Sep 27ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 14Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
Jan 24ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech
Oct 14Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?
Oct 08ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09
Aug 11ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 24We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Mar 08We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Nov 23We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Aug 05ORIC Pharmaceuticals EPS beats by $0.04
May 06Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation
Apr 16We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Jan 01Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101
Dec 21Oric Pharma prices stock offering at $23
Nov 13Analisi delle retribuzioni degli amministratori delegati
Data | Compenso totale | Stipendio | Guadagni aziendali |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$111m |
Mar 31 2024 | n/a | n/a | -US$102m |
Dec 31 2023 | US$3m | US$596k | -US$101m |
Sep 30 2023 | n/a | n/a | -US$93m |
Jun 30 2023 | n/a | n/a | -US$93m |
Mar 31 2023 | n/a | n/a | -US$90m |
Dec 31 2022 | US$4m | US$572k | -US$89m |
Sep 30 2022 | n/a | n/a | -US$91m |
Jun 30 2022 | n/a | n/a | -US$85m |
Mar 31 2022 | n/a | n/a | -US$85m |
Dec 31 2021 | US$7m | US$536k | -US$79m |
Sep 30 2021 | n/a | n/a | -US$84m |
Jun 30 2021 | n/a | n/a | -US$91m |
Mar 31 2021 | n/a | n/a | -US$81m |
Dec 31 2020 | US$6m | US$489k | -US$74m |
Sep 30 2020 | n/a | n/a | -US$54m |
Jun 30 2020 | n/a | n/a | -US$35m |
Mar 31 2020 | n/a | n/a | -US$30m |
Dec 31 2019 | US$672k | US$456k | -US$27m |
Dec 31 2018 | US$2m | US$290k | -US$21m |
Compensazione vs Mercato: La retribuzione totale di Jacob ($USD 3.15M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 3.30M ).
Compensazione vs guadagni: La retribuzione di Jacob è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Jacob Chacko (45 yo)
6.3yrs
Mandato
US$3,153,083
Compensazione
Dr. Jacob M. Chacko, M.D., MBA, has been Chief Executive Officer and Director of ORIC Pharmaceuticals, Inc. since May 2018 and has been its President since May 2019. Dr. Chacko joined the ORIC Pharmaceutic...
Gruppo dirigente
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
Co-Founder | 9.4yrs | US$186.87k | 0.32% $ 2.3m | |
President | 6.3yrs | US$3.15m | 1.03% $ 7.4m | |
Chief Financial Officer | 4.9yrs | US$1.45m | 0.12% $ 852.4k | |
Chief Medical Officer | 5.9yrs | US$1.51m | 0.034% $ 242.1k | |
Co-Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
Co-Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
Chief Scientific Officer | 5.1yrs | Nessun dato | Nessun dato | |
General Counsel | 4.3yrs | Nessun dato | Nessun dato | |
VP & Head of People | 1.9yrs | Nessun dato | Nessun dato | |
Senior Vice President of Clinical Development | 5.4yrs | Nessun dato | Nessun dato | |
Chief Business Officer | 5.8yrs | Nessun dato | Nessun dato |
5.3yrs
Durata media
57yo
Età media
Gestione esperta: Il team dirigenziale di ORIC è esperto e expertise (durata media dell'incarico 5.3 anni).
Membri del Consiglio di amministrazione
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
Co-Founder | 9.4yrs | US$186.87k | 0.32% $ 2.3m | |
President | 6.3yrs | US$3.15m | 1.03% $ 7.4m | |
Co-Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
Co-Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
Independent Director | 2.8yrs | US$140.37k | 0% $ 0 | |
Independent Director | 4.2yrs | US$133.87k | 0.029% $ 208.5k | |
Independent Director | 4.5yrs | US$147.87k | 0% $ 0 | |
Independent Director | 3yrs | US$141.37k | 0% $ 0 |
4.3yrs
Durata media
62.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ORIC sono considerati esperti (durata media dell'incarico 4.3 anni).